EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Restoring Control: Real-World Success with Imipenem–Relebactam in Critical MDR Infections—A Multicenter Observational Study

Andrea Marino iD, Giuseppe Pipitone iD, Emmanuele Venanzi Rullo iD, Federica Cosentino, Rita Ippolito, Roberta Costa, Sara Bagarello, Ylenia Russotto iD, Chiara Iaria, Bruno Cacopardo, Giuseppe Nunnari iD

Pathogens · 11.07.2025 · 14 (7) · 685

DOI: 10.3390/pathogens14070685 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pathogens, online erschienen am 11.07.2025. Verfasst von Andrea Marino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy. Hauptthemen laut MEDLINE: Imipenem, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Azabicyclo Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multidrug-resistant (MDR) Gram-negative infections, particularly those caused by carbapenem-resistant Enterobacterales (CRE) and difficult-to-treat Pseudomonas aeruginosa (DTR-Pa), present a growing global healthcare challenge, especially in critically ill populations. Imipenem–relebactam (I/R), a novel β-lactam/β-lactamase inhibitor combination, has shown efficacy in clinical trials, but real-world data remain limited.

Methods

We conducted a multicenter, retrospective–prospective observational study across tertiary-care hospitals in Italy between January 2020 and May 2025. Adult patients (≥18 years) treated with I/R for ≥48 h for suspected or confirmed MDR Gram-negative infections were included. Primary endpoints were clinical success at the end of therapy and 30-day all-cause mortality. Secondary endpoints included microbiological eradication, recurrence, safety, and predictors of treatment failure. Statistical analysis involved descriptive methods and correlation analysis for mortality predictors.

Results

Twenty-nine patients were included (median age 66 years; 58.6% ICU admission; 71.4% mechanical ventilation). Clinical success was achieved in 22/29 patients (75.9%), while 30-day mortality was 24.1% (7/29). The most common pathogen was Klebsiella pneumoniae (62.1%), with 41.4% of infections being polymicrobial. Microbiological eradication was confirmed in all the BSIs. Parenteral nutrition (p = 0.016), sepsis at presentation (p = 0.04), candidemia (p = 0.036), and arterial catheter use (p = 0.029) were significantly more frequent in non-survivors. Survivors showed significant reductions in CRP, PCT, and bilirubin at 48 h, while non-survivors did not. Parenteral nutrition (rho = 0.427, p = 0.023), sepsis (rho = 0.378, p = 0.043), and arterial catheter use (rho = 0.384, p = 0.04) were significantly correlated with mortality.

Conclusions

In this Italian multicenter cohort of critically ill patients, imipenem–relebactam demonstrated high clinical success and acceptable mortality rates in the treatment of severe MDR Gram-negative infections, particularly those caused by KPC-producing K. pneumoniae. Early biomarker dynamics may aid in monitoring treatment response. Larger prospective studies are needed to confirm these findings and define optimal treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImipenemAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialAzabicyclo CompoundsGram-Negative Bacterial Infectionsbeta-Lactamase InhibitorsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesItalyTreatment OutcomeProspective StudiesCritical Illness

Stichwörter der Autor:innen

EnterobacteralesKlebsiella pneumoniaeMDR bacteriaPseudomonas aeruginosaantimicrobial stewardshipimipenem-relebactam

Substanzen

ImipenemrelebactamAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy.
  • Infectious Diseases Unit, ARNAS Civico-Di Cristina, 90127 Palermo, Italy.
  • Unit of Infectious Diseases, G. Martino University Hospital, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.
  • Infectious Diseases Unit, University Hospital P. Giaccone, 90127 Palermo, Italy.

ORCID-Profile: Andrea Marino, Giuseppe Pipitone, Emmanuele Venanzi Rullo, Ylenia Russotto, Giuseppe Nunnari

Zitieren

APA

Marino, A., Pipitone, G., Venanzi Rullo, E., Cosentino, F., Ippolito, R., Costa, R., Bagarello, S., Russotto, Y., Iaria, C., Cacopardo, B., & Nunnari, G. (2025). Restoring Control: Real-World Success with Imipenem–Relebactam in Critical MDR Infections—A Multicenter Observational Study. Pathogens, 14(7), 685. https://doi.org/10.3390/pathogens14070685

Vancouver

Marino A, Pipitone G, Venanzi Rullo E, Cosentino F, Ippolito R, Costa R, et al. Restoring Control: Real-World Success with Imipenem–Relebactam in Critical MDR Infections—A Multicenter Observational Study. Pathogens. 2025;14(7):685. doi:10.3390/pathogens14070685

BibTeX
@article{Marino2025,
  author = {Marino, Andrea and Pipitone, Giuseppe and Venanzi Rullo, Emmanuele and Cosentino, Federica and Ippolito, Rita and Costa, Roberta and Bagarello, Sara and Russotto, Ylenia and Iaria, Chiara and Cacopardo, Bruno and Nunnari, Giuseppe},
  title = {Restoring Control: Real-World Success with Imipenem–Relebactam in Critical MDR Infections—A Multicenter Observational Study},
  journal = {Pathogens},
  year = {2025},
  volume = {14},
  number = {7},
  pages = {685},
  doi = {10.3390/pathogens14070685}
}
Kostenlos starten →